Compare BZUN & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZUN | TLSA |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.7M | 155.2M |
| IPO Year | N/A | 2017 |
| Metric | BZUN | TLSA |
|---|---|---|
| Price | $2.20 | $1.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 192.1K | 109.7K |
| Earning Date | 03-25-2026 | 05-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.10 | N/A |
| Revenue Next Year | $3.93 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.12 | $0.73 |
| 52 Week High | $4.88 | $2.60 |
| Indicator | BZUN | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 27.06 | 42.67 |
| Support Level | N/A | N/A |
| Resistance Level | $3.05 | $1.56 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 11.27 | 21.62 |
Baozun Inc is engaged to provide its customers with end-to-end e-commerce solutions including the sales of apparel, home and electronic products, online store design and setup, visual merchandising and marketing, online store operations, customer services, warehousing and order fulfillment, as well as the holistic brand management, including strategy and tactic positioning, branding and marketing, retail and e-commerce operations, supply chain and logistics, and technology empowerment. It has two operating segments: E-Commerce (encompassing BEC and BZI) and Brand Management (representing BBM). The company generates maximum of its revenue from E-Commerce (encompassing BEC and BZI) segment.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.